Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 5 February 2020. Rich Kaeser.

Executive Summary

Medtech counterfeiters are endangering the lives of US patients with their illicit trade in counterfeit devices to American hospitals, and Congress could assist by giving the FDA the authority to destroy the fakes, Johnson & Johnson executive Rich Kaeser says. Check out his comments here.

“Lawmakers play a critical role in strengthening our nation’s laws to reduce incentives for engaging in illegal trade. As such, Johnson & Johnson is very pleased to support H.R. 5663, the ‘Safeguarding Therapeutics Act,’ which extends FDA authority to destroy counterfeit devices and combination products valued at $2,500 or less.” – Rich Kaeser, VP of global brand protection, Johnson & Johnson

Click here for a free trial of Medtech Insight

 

Related Content

Topics

UsernamePublicRestriction

Register

MT126207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel